Janux Therapeutics Q1 2026 Earnings Report

Janux Therapeutics EPS Results

• Actual EPS: N/A
• Consensus EPS: -$0.52
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Janux Therapeutics Revenue Results

• Actual Revenue: N/A
• Expected Revenue: $4.36 million
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Janux Therapeutics Announcement Details

• Quarter: Q1 2026
• Date: 5/14/2026
• Time: Before Market Opens
• Conference Call Date: Friday, May 15, 2026
• Conference Call Time: 4:00PM ET

Janux Therapeutics (NASDAQ:JANX) is a clinical-stage biotechnology company focused on developing next-generation intratumoral immuno-oncology therapies that harness the body’s innate and adaptive immune systems. The company designs and synthesizes proprietary Toll-like receptor (TLR) agonists to reprogram the tumor microenvironment. Janux is publicly traded on the Nasdaq under the symbol JANX.

Its lead programs include JTX-8064, a fully synthetic TLR4 agonist engineered for optimal stability and potency, and JTX-4014, a TLR1/2 agonist formulated for direct intratumoral administration. By activating key pathways of the innate immune response, these candidates aim to recruit and amplify antitumor T-cell activity while minimizing systemic exposure. Janux’s pipeline is advancing through early-stage clinical trials to evaluate safety, tolerability and preliminary signals of efficacy in a variety of solid tumors.

Based in San Diego, Janux leverages collaborations with contract research organizations and academic centers to support manufacturing and clinical development. The company’s leadership team comprises experienced immuno-oncology researchers and drug developers with backgrounds in biologics, formulation science and regulatory strategy. Janux continues to build its infrastructure and partnerships to accelerate the translation of its TLR agonists from preclinical research into potential new treatment options for cancer patients.